Cutler Group’s 9 Meters Biopharma NMTR Stock Holding History

Cutler Group’s Portfolio NMTR Stock Details NMTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-90	Closed	-$42K	–	4797
2018 Q3	$42K	Sell	90 -300	-77%	-$51.5K	﹤0.01%	1726
2018 Q2	$44K	Buy	+390	New	+$143K	﹤0.01%	1690

Other funds holding NMTR

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

ODFS

O'Donnell Financial Services San Rafael, California $290M AUM 15.6% 1-Year Est. Return

Cutler Group's NMTR Position: Q4 2022 in Review

Cutler Group sold out of 9 Meters Biopharma (NMTR) in Q4 2022, closing a stake of 220 shares.

Cutler Group first reported a position in NMTR in Q2 2018 and held it in 18 quarters. The position peaked at $58K in Q2 2018. 42 funds tracked by Wall St. Rank hold NMTR as of Q4 2022.

Cutler Group reported no remaining 9 Meters Biopharma position as of Q4 2022 after selling out during the quarter.
Cutler Group sold 220 9 Meters Biopharma shares in Q4 2022.
Cutler Group first reported a position in 9 Meters Biopharma in Q2 2018 and held it in 18 quarters.
Cutler Group's 9 Meters Biopharma position peaked at $58K in Q2 2018.
42 funds tracked by Wall St. Rank held 9 Meters Biopharma as of Q4 2022.

Based on Cutler Group's 13F filing for Q4 2022, filed 7 Feb 2023.